Skip to main content

Skin Diseases

13
Pipeline Programs
9
Companies
8
Clinical Trials
2 recruiting
7
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
0
0
0
2
9
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
2100%
+ 11 programs with unclassified modality

On Market (7)

Approved therapies currently available

GSK
FLOVENT HFAApproved
fluticasone propionate
GSK
inhalation2004
395M Part D
Pfizer
TYGACILApproved
tigecycline
Pfizer
Tetracycline-class Antibacterial [EPC]intravenous2005
85K Part D
GSK
FLOVENT DISKUS 250Approved
fluticasone propionate
GSK
inhalation2000
GSK
FLOVENT DISKUS 100Approved
fluticasone propionate
GSK
inhalation2000
GSK
FLONASE ALLERGY RELIEFApproved
fluticasone propionate
GSK
nasal2014
GSK
FLONASEApproved
fluticasone propionate
GSK
nasal1994
GSK
FLOVENT DISKUS 50Approved
fluticasone propionate
GSK
inhalation2000

Competitive Landscape

9 companies ranked by most advanced pipeline stage

ViiV Healthcare
ViiV HealthcareNC - Durham
4 programs
1
2
3% Benzoyl PeroxidePhase 4
Fluticasone propionatePhase 4
MinocyclinePhase 1Small Molecule
Substance PN/A
GSK
GSKLONDON, United Kingdom
2 programs
1
Substance PN/A1 trial
Fluticasone propionatePHASE_41 trial
Active Trials
NCT04676763Completed32Est. Jul 2021
NCT01915914Completed107Est. Feb 2015
Pfizer
PfizerNEW YORK, NY
1 program
1
1
TigecyclinePhase 3Small Molecule1 trial
Active Trials
NCT00911573Withdrawn0Est. May 2014
AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
1 program
1
DaptomycinPhase 31 trial
Active Trials
NCT00772447Completed265Est. Sep 2010
Prevail Therapeutics
1 program
1
LY3041658Phase 1
Apollo Therapeutics
Apollo TherapeuticsUK - Cambridge
1 program
ApolloVue™ S100 image system, Viper1-S003N/A1 trial
Active Trials
NCT04066582Completed123Est. Oct 2019
Human BioSciences
Human BioSciencesWV - Martinsburg
1 program
Deep Phenotyping of CIndUN/A1 trial
Active Trials
NCT07359430Recruiting40Est. Jun 2026
Martin Pharmaceuticals
1 program
Micro-plasmapheresisN/A1 trial
Active Trials
NCT00186563Completed13
BeOne Medicines
BeOne MedicinesCA - San Carlos
1 program
BG-A3004PHASE_11 trial
Active Trials
NCT07412691Recruiting98Est. Aug 2028

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
GSKFluticasone propionate
PfizerTigecycline
AstraZenecaDaptomycin
BeOne MedicinesBG-A3004
Human BioSciencesDeep Phenotyping of CIndU
GSKSubstance P
Apollo TherapeuticsApolloVue™ S100 image system, Viper1-S003

Clinical Trials (8)

Total enrollment: 678 patients across 8 trials

NCT01915914GSKFluticasone propionate

A Randomized, Open-label, Comparative Study to Evaluate an Intermittent Dosing Regimen of Fluticasone Propionate 0.05% Cream (Twice Per Week) in Reducing the Risk of Relapse When Added to Regular Daily Moisturization Using PHYSIOGEL Lotion in Paediatric Subjects With Stabilized Atopic Dermatitis

Start: Dec 2013Est. completion: Feb 2015107 patients
Phase 4Completed

Study Evaluating Tigecycline Versus Clindamycin Or Vancomycin On Complicated Skin And Skin Structure Infections Including Those Due To Methicillin-Resistant Staphylococcus Aureus (MRSA) In Pediatric Subjects

Start: Aug 2011Est. completion: May 20140
Phase 3Withdrawn

China Registration Study in Patients With Skin Infections

Start: Sep 2008Est. completion: Sep 2010265 patients
Phase 3Completed

A Study to Evaluate the Safety of BG-A3004 in Healthy Participants and Patients With Immune-Mediated Skin Diseases

Start: Mar 2026Est. completion: Aug 202898 patients
Phase 1Recruiting

A Human In-vivo Model for the Detection of Inflammatory and Nociceptive Biomarkers

13 patients
N/ACompleted
NCT07359430Human BioSciencesDeep Phenotyping of CIndU

Deep Phenotyping of CIndU

Start: Jan 2025Est. completion: Jun 202640 patients
N/ARecruiting
NCT04676763GSKSubstance P

Substance P Challenge in Healthy Participants

Start: Mar 2021Est. completion: Jul 202132 patients
N/ACompleted
NCT04066582Apollo TherapeuticsApolloVue™ S100 image system, Viper1-S003

Early Feasibility Study: Application of OCT Imaging in Dermatology

Start: Jan 2018Est. completion: Oct 2019123 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 late-stage (Phase 3) programs, potential near-term approvals
2 actively recruiting trials targeting 678 patients
9 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.